(Q48158307)

9 February 2018

title

Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease (English)

1 reference

9 February 2018

author name string

P T Ménnistó

series ordinal

1

1 reference

9 February 2018

publication date

1 March 1994

1 reference

9 February 2018

published in

CNS Drugs

1 reference

9 February 2018

volume

1

1 reference

9 February 2018

issue

3

1 reference

9 February 2018

page(s)

172-179

1 reference

9 February 2018

https://scigraph.springernature.com/pub.10.2165/00023210-199401030-00002

exact match

0 references

cites work

Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography

1 reference

12 December 2020

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

1 reference

12 December 2020

Purification and partial sequence analysis of the soluble catechol-O-methyltransferase from human placenta: comparison to the rat liver enzyme

1 reference

12 December 2020

Computerized rotometer apparatus for recording circling behavior

1 reference

12 December 2020

The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition

1 reference

12 December 2020

COMT inhibition with nitecapone does not affect the tyramine pressor response

1 reference

12 December 2020

Catechol-O-methyl transferase: pharmacological aspects and physiological role

1 reference

12 December 2020

Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats

1 reference

12 December 2020

Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease

1 reference

12 December 2020

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

1 reference

12 December 2020

Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone

1 reference

12 December 2020

Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice

1 reference

12 December 2020

Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form

1 reference

12 December 2020

Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.

1 reference

12 December 2020

Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase.

1 reference

12 December 2020

Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo

1 reference

12 December 2020

Purification and partial characterization of rat liver soluble catechol-O-methyltransferase.

1 reference

12 December 2020

Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats

1 reference

12 December 2020

Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.

1 reference

12 December 2020

18F‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462)

1 reference

12 December 2020

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa

1 reference

12 December 2020

Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone

1 reference

12 December 2020

Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

12 December 2020

Kinetics of rat brain soluble catechol-O-methyltransferase and its inhibition by substrate analogues

1 reference

12 December 2020

[18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine

1 reference

12 December 2020

Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors

1 reference

12 December 2020

New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

1 reference

12 December 2020

Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.

1 reference

12 December 2020

Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase

1 reference

12 December 2020

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease

1 reference

12 December 2020

CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure

1 reference

12 December 2020

Acute Toxicity of Three New Selective COMT Inhibitors in Mice with Special Emphasis on Interactions with Drugs Increasing Catecholaminergic Neurotransmission

1 reference

12 December 2020

Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues

1 reference

12 December 2020

Cloning and Characterization of Human Placental Catechol--Methyltransferase cDNA

1 reference

12 December 2020

Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study

1 reference

12 December 2020

Molecular cloning and characterization of rat liver catechol-O-methyltransferase

1 reference

12 December 2020

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

1 reference

12 December 2020

Central action of benserazide after COMT inhibition demonstrated in vivo by PET

1 reference

12 December 2020

Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum

1 reference

12 December 2020

Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats

1 reference

12 December 2020

10.2165/00023210-199401030-00002

Identifiers

DOI

1 reference

9 February 2018

Dimensions Publication ID

1044773814

0 references

1 reference

9 February 2018